|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 had the best change in log likelihood when added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, dyslipidaemia and FG.
|
27611701 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21), liver-derived hormone, exerts diverse metabolic effects, being considered for clinical application to treat obesity and diabetes.
|
28374855 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 prevents the onset of diet-induced diabetes, without changing body fat mass.
|
28770320 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21) is a major metabolic regulator that has been shown to be elevated in a number of metabolic disturbances including type 2 diabetes mellitus (T2DM) and the metabolic syndrome, but few studies about the relationship between serum FGF21 and the complications of diabetes have been done.
|
29285020 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF-21) is an important regulator in glycolipid metabolism that is a promising drug candidate for treatment of diabetes and obesity.
|
31129207 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21) is closely linked with metabolic disorders including diabetes.
|
31205953 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor 21 (FGF21) is a potential diabetic drug, however, it has not been investigated whether FGF21 prevents neointima hyperplasia in DM.
|
31513948 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
FGF21 acts mainly on adipose tissue and ectopic fat accumulation is a typical feature in metabolic deterioration such as diabetes, metabolic syndrome, and cardiovascular disease.
|
31798902 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Associations of fibroblast growth factor 21 with cardiovascular risk and β-cell function in patients who had no history of diabetes.
|
28735064 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Brown adipose tissue (BAT)-dependent thermogenesis and its suggested augmenting hormone, FGF21, are potential therapeutic targets in current obesity and diabetes research.
|
28768181 |
2017 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Circulating FGF21 level was independently associated with CIN (aOR: 4.66, 95% CI: 1.29-16.86, p = 0.019) and renal function decline (aHR: 7.98, 95% CI: 4.07-15.66, p < 0.001) whether diabetes was present or not.
|
30127382 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
During the past decade, there has been an enormous effort made to understand the physiological roles of FGF21 in regulating metabolism and to identify the mechanism for its potent pharmacological effects to reverse diabetes and obesity.
|
29727594 |
2018 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Female gender, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), waist circumference (WC), body weight (BW), body mass index (BMI), body fat mass, fasting glucose, glycated hemoglobin level (HbA1c), triglyceride level (TG), urine albumin-to-creatinine ratio (UACR), insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), and FGF21 levels were higher, whereas high-density lipoprotein cholesterol level (HDL-C) and estimated glomerular filtration rate (eGFR) were lower in DM patients with MetS.
|
31582974 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fibroblast growth factors 19 and 21 (FGF19 and FGF21) have been implicated, independently, in type 2 diabetes (T2D) but it is not known if their circulating levels correlate with each other or whether the associated hepatic signaling mechanisms that play a role in glucose metabolism are dysregulated in diabetes.
|
25664662 |
2015 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
HDAC3 inhibition in diabetic mice may activate Nrf2 preventing diabetes-induced liver damage and FGF21 synthesis and secretion leading to aortic protection.
|
29634312 |
2018 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher levels of FGF21 were expressed, particularly in patients with diabetes.
|
30959789 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Induction of diabetes increased FGF21 levels and both of the treatments could reduce its contents, however, glibenclamide was more effective than HESS.
|
31655149 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Metallothionein can modulate various stress-induced signaling pathways (mitogen-activated protein kinase, Wnt, nuclear factor-κB, phosphatidylinositol 3-kinase, sirtuin 1/AMP-activated protein kinase and fibroblast growth factor 21) to alleviate diabetes and diabetic complications.
|
29072367 |
2018 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis showed that FGF-21 level was associated with hepatic steatosis (OR 1.005, 95% CI 1.001-1.009) and F3/F4 (OR 0.993, 95% CI 0.989-0.998), while AFABP level (OR 1.001, 95% CI 1-1.002), body mass index (BMI) (OR 1.107, 95% CI 1.037-1.182) and presence of diabetes mellitus (OR 2.059, 95% CI 1.206-3.516) were associated with F3/F4.
|
30912255 |
2019 |
|
Diabetes Mellitus
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Muscle transcriptome analysis revealed the induction of mitochondrial biogenesis, down-regulation of diabetes-related genes, and increased expression of the genes encoding the myokines FGF21 and GDF15.
|
28223503 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous studies have been conducted to establish and confirm whether FGF21 exerts beneficial effects on obesity and diabetes along with its complications.
|
29989062 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our aims were to examine the add-on effects of a sodium-glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes.
|
31721467 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have indicated that fibroblast growth factor 21 (FGF21), an attractive and potential therapeutic treatment for DM, may exert diverse effects in the central nervous system.
|
30785085 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies have reported that FGF21 is expected to become a new drug for treatment of diabetes.
|
28143735 |
2017 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies showed that FGF21 ameliorated and prevented the development of metabolic disorders, such as obesity and diabetes mellitus.
|
30991048 |
2019 |